What a pleasure it was to meet Donghoon Shin! His passion and desire to learn from patient advocates was genuine and impressive. The future of #lungcancer research is bright😎
#LCSM #EGFR
What a pleasure it was to meet Donghoon Shin! His passion and desire to learn from patient advocates was genuine and impressive. The future of #lungcancer research is bright😎
#LCSM #EGFR
Congrats Donghoon Shin on receiving an honorable mention at the @EGFRSummit Your research and passion for the field are truly impressive #ProudMentor
Huge shoutout to @EGFRResisters for giving trainees a platform to showcase their work! #LCSM 🙌🏼 @jillfeldman4.bsky.social
The durva approval for limited stage small cell lung cancer made my day
I had a throughout conversation with my patient just two days ago, and now it’s been approved!
www.fda.gov/drugs/resour...
Just finished my first week of inpatient service as an attending!
I’m deeply grateful for the growth of my professional career and for the patients who have been a part of this journey. #IMG #MedEd
Updated treatment algorithms for breast cancer now include adjuvant ribociclib and inavolisib, along with key trial names. Thrilled to see we're truly running out of space in HR+ disease—progress is here, with much more to come for all breast cancer subtypes!
17.11.2024 23:03 — 👍 71 🔁 16 💬 3 📌 2
📢 The @ASCO released updated living guidelines for treating stage IV #NSCLC with driver alterations! ascopubs.org/doi/10.1200/....
This is no easy feat, but it was an honor to work alongside exceptional experts dedicated to providing the most up-to-date, evidence-based guidance.
#LCSM #LCAM
We are excited to be Shining the Spotlight on the work of Rising 🌟, Dr. Ivy Riano of Dartmouth as she discusses Broadened Eligibility Criteria in Lung Cancer Clinical Trials for Patients w Brain Metastasis on MedNews Week Medical Spotlight in partnership w OncLive.
www.onclive.com/view/adoptin...